Macromolecular prodrugs V. Polymer-broxuridine conjugates
D. Maysinger1995, International Journal of Pharmaceutics
Sign up for access to the world's latest research
checkGet notified about relevant papers
checkSave papers to use in your research
checkJoin the discussion with peers
checkTrack your impact
Abstract
Broxuridine (BrdU) was covalently bound to a,/3-poly[(2-hydroxyetbyl)-oL-aspartamide] (PHEA) and ct,/3poly[(2-aminoethyl)-DL-aspartamide]-a,/3-poly[(2-hydroxyethyl)-DL-aspartamide] (PAHA). BrdU was first chemically modified to 3'-O-acetyl-5'-O-chloroformyl-5-bromo-2'-deoxyuridine (AcCBrdU) and 3'-O-acetyl-5'-O-phosphooxydichloride-5-bromo-2'-deoxyuridine (AcPBrdU). These compounds were bound to PHEA by carbonate and phosphodiester linkages, respectively. 5-Bromo-2'-deoxyuridine 5'-monophosphate (PBrdU) was linked to PAHA by an amide type bond. Neuroepithelial cells were used as a model system to assess the suitability of the conjugated BrdU for cell proliferation. Parallel experiments were performed with unconjugated BrdU and the extent of incorporation into DNA was determined by immunocytochemistry using an BrdU antibody. The results from these studies suggest that conjugated BrdU can be used as an alternative to currently used means of BrdU delivery.
Related papers
Preparation, characterization and release of microencapsulated bromodeoxyuridine
Life Sciences, 1994
Biodegradable and biocompatible microspheres with bromodeoxyuridine (BrUrd) have been prepared, characterized and tested in vitro and in vivo. Scanning electron microscopy and image analysis revealed regular spherical shapes and an average size -I-SD of 2.47 _ 0.59/xm. Total content of BrUrd as determined by HPLC was within the range of 0.2 -1.5%. Kinetic analyses of two different preparations showed similar release half-times (approx. 12 hrs), kinetic constants -0.0556, -0.0564, and -0.0557, -0.0597 [h-l], and correlation coefficients of 0.998, and 0.999 when fitted to the first order or biphasic first order kinetics, respectively. Preliminary data from immunocytochemical studies revealed efficient incorporation of BrUrd delivered from these microcapsules into nuclei of proliferating cells surrounding brain lesions in rats.
Polymeric drugs based on conjugates of synthetic and natural macromolecules
Journal of Controlled Release, 2000
This paper describes the synthesis, physico-chemical characteristics and results of selected biological tests of conjugates of antibodies or proteins with poly(HPMA) or with poly(HPMA) carriers of anti-cancer drug doxorubicin, designed for targeted cancer therapy. Two types of conjugates differing in the method of conjugation of polymer with protein were synthesized. In the first, protein is attached to the polymer via an oligopeptide sequence in the side chain of the polymer backbone and, in the second, the polymer is attached to protein via its end-chain functional group. Conjugation of an antibody with poly(HPMA) does not influence the binding activity of the antibody for cell surface antigen. The physico-chemical characteristics and biological activity of both systems depend on the detailed structure of the polymer, the type of antibody or protein moiety and the structure of the whole system.
Polyaspartamide-Doxorubicin Conjugate as Potential Prodrug for Anticancer Therapy
Pharmaceutical Research, 2014
Purpose To synthesize a new polymeric prodrug based on α,βpoly(N-2-hydroxyethyl)(2-aminoethylcarbamate)-d,l-aspartamide copolymer bearing amine groups in the side chain (PHEA-EDA), covalently linked to the anticancer drug doxorubicin and to test its potential application in anticancer therapy. Methods The drug was previously derivatized with a biocompatible and hydrophilic linker, leading to a doxorubicin derivative highly reactive with amino groups of PHEA-EDA. The PHEA-EDA-DOXO prodrug was characterized in terms of chemical stability. The pharmacokinetics, biodistribution and cytotoxicity of the product was investigated in vitro and in vivo on human breast cancer MCF-7 and T47D cell lines and NOD-SCID mice bearing a MCF-7 human breast carcinoma xenograft. Data collected were compared to those obtained using free doxorubicin. Results The final polymeric product is water soluble and easily hydrolysable in vivo, due to the presence of ester and amide bonds along the spacer between the drug and the polymeric backbone. In vitro tests showed a retarded cytotoxic effect on tumor cells, whereas a significant improvement of the in vivo antitumor activity of PHEA-EDA-DOXO and a survival advantage of the treated NOD-SCID mice was evidenced, compared to that of free doxorubicin.
Sterically stabilized polyplex: ligand-mediated activity
Journal of Controlled Release, 2001
Synthetic vectors have been considered as a safer and more versatile alternative to viral-based gene delivery systems. A variety of very simple synthetic vector systems, e.g., cationic lipid-and polymer-complexed plasmid DNA have activity in vivo but it appears to be mediated by non-specific electrostatic interactions limiting targeting. In order to avoid these problems, we designed a sterically stabilized layered colloidal system. The steric polymer coating reduces non-specific interactions. We have synthesized a PEG conjugate of PEI that complexes DNA to form small, stable colloids with a steric polymer coat on their surface. The polymer enhances colloidal stability and reduces non-specific binding and toxicity. It also renders the complex inactive presumably due to reduced binding. Ligands are then appended to the distal end of the steric polymer to restore cell binding and expression at target cells. We prepared conjugates with RGD peptide ligands appended to the distal end of the steric polymer. The resulting conjugates also form complexes but with ligands exposed on their surface restoring binding and activity. Labeled oligonucleotides and DNA were used to measure intracellular distribution. Oligonucleotides are found localized in the nucleus, whereas the labeled plasmid DNA remained in the cytoplasm. Import of plasmid DNA into the nucleus appears to be very inefficient yet sufficient for expression.
Bromomaleimide-Linked Bioconjugates Are Cleavable in Mammalian Cells
ChemBioChem, 2012
ProTides of BVdU as potential anticancer agents upon efficient intracellular delivery of their activated metabolites
Bioorganic & medicinal chemistry letters, 2016
Nucleosides represent a major chemotherapeutic class for treating cancer, however their limitations in terms of cellular uptake, nucleoside kinase-mediated activation and catabolism are well-documented. The monophosphate pro-nucleotides known as ProTides represents a powerful strategy for bypassing the dependence on active transport and nucleoside kinase-mediated activation. Herein, we report the structural tuning of BVdU ProTides. Forty six phosphoramidates were prepared and biologically evaluated against three different cancer cell lines; murine leukemia (L1210), human CD4(+) T-lymphocyte (CEM) and human cervical carcinoma (HeLa). Twenty-fold potency enhancement compared to BVdU was achieved against L1210 cells. Interestingly, a number of ProTides showed low micromolar activity against CEM and HeLa cells compared to the inactive parent BVdU. The ProTides showed poor, if any measurable toxicity to non-tumourigenic human lung fibroblast cell cultures. Separation of four pairs of the...
Effect of poly(ethylene imine) molecular weight and pegylation on organ distribution and pharmacokinetics of polyplexes with oligodeoxynucleotides in mice. Drug Metab Dispos
Drug Metabolism and Disposition
The in vivo body distribution and the pharmacokinetics of a 20mer double-stranded nuclear factor B decoy oligodeoxynucleotide (ODN) complexed with 25-kDa poly(ethylene imine) (PEI), low molecular weight 2.7-kDa PEI, and PEGylated PEI [bPEI(25k)-g-lPEG(550) 50 ] after intravenous injection were studied in BALB/c mice using a double-labeling technique to follow simultaneously the distribution of both complex components. The polymers were radioactively labeled with 125 I by Bolton-Hunter reagent and the decoys with [␥-32 P]ATP by an enzymatic 5-end-labeling technique. After i.v. bolus injections into the jugular vein, organ samples were taken after 15 min, 2 h and 12 h. For pharmacokinetic studies blood and plasma samples were collected from 20 s up to 2 h. Uncomplexed decoy was found to be degraded already after 15 min and was rapidly eliminated renally into urine. Complexation with the homopolymers increased the organ levels and circulation time of ODN after 15 min, with similar organ distribution profiles for 125 I and 32 P. In contrast to the behavior of free ODN, the complexes were mainly distributed into liver and spleen. Whereas the organ concentrations of 125 I remained high over 12 h, the 32 P values of ODN decreased in a time-dependent manner, likely due to separation of the complexes and degradation of the DNA. Although PEGylated PEI demonstrated a slower 125 I-uptake into the RES organs compared with 25-kDa PEI due to the shielding effect of PEG [poly(ethylene glycol)], it was not able to better stabilize the complexes in the circulation or protect DNA from degradation. ABBREVIATIONS: PEI, poly(ethylene imine); AUC, area under the curve; LMW, low molecular weight; NF-B nuclear factor B; ODN, oligodeoxynucleotide; PEG, poly(ethylene glycol); T4 PNK, T4 polynucleotide kinase; TCA, trichloroacetic acid; PEI(PEG) 50 , bPEI(25k)-g-lPEG(550) 50 ; N/P ratio, total nitrogen of the polymer per DNA phosphate ratio; %ID, percentage of injected dose; ANOVA, analysis of variance; RES, reticuloendothelial system.
Targeting of tumor cells and DNA by a chlorambucil-spermidine conjugate
Cancer research, 1992
Many tumor cells, including murine ADJ/PC6 plasmacytoma cells, possess an active energy dependent polyamine uptake system which selectively accumulates endogenous polyamines and structurally related compounds. We have attempted to target the cytotoxic drug chlorambucil to a tumor possessing this uptake system by conjugating it to the polyamine spermidine. Furthermore, since polyamines have a high affinity for DNA, the attachment of spermidine to chlorambucil should also facilitate its targeting to DNA. This was supported by the observation that the chlorambucil-spermidine conjugate was approximately 10,000-fold more active than chlorambucil at forming interstrand crosslinks with naked DNA. In vitro cytotoxicity and in vivo antitumor studies were carried out using the ADJ/PC6 plasmacytoma. In vitro, using [3H]thymidine incorporation to assess cell viability following a 1-h exposure to control and polyamine depleted ADJ/PC6 cells, chlorambucil-spermidine was 35- and 225-fold, respecti...
Polymeric Conjugates of 9-[2-(Phosphonomethoxy)ethyl]purine with Potential Antiviral and Cytostatic Activity
Collection of Czechoslovak Chemical Communications, 2006
Syntheses and characterization of polymer conjugates of 9-[2-(phosphonomethoxy)ethyl] (PME) derivatives of adenine (PMEA), 2,6-diaminopurine (PMEDAP) and guanine (PMEG) are described. The phosphonate group of these acyclic nucleotide analogues was activated by reaction with triphenylphosphine and di(2-pyridyl) disulfide (TPP-PDS). The activated phosphonate reacted with a random copolymer containing N-(2-hydroxypropyl)methacrylamide (HPMA) and N-(3-methacrylamidopropanoyl)ethane-1,2-diamine (Ma-AP-ED) units. The phosphonamide bond between the nucleotide and polymer carrier proved to be relatively stable at physiological pH 7.4 while at pH 5.0 (corresponding to endosomal or lysosomal compartments of cells) underwent slow hydrolysis. The rate of hydrolysis (drug release) was shown to depend on the detailed structure of the heterocyclic base. The polymer-drug conjugates described in the paper represent a new family of antiviral and cytostatic drugs with potentially improved pharmacokine...
Macromolecules Applied to Pharmaceutical Chemistry
Molecules, 2005
Macromolecular and polymer science have evolved significantly over the past few years, with remarkable advances in many areas such as polymeric drugs, self-assembly systems, implant materials, drug delivery systems and controlled drug release. These areas have now become well established in the realm of multidisciplinary technology and science. An increasing number of applications of macromolecules have required a covalent attachment of the polymers to a wide range of substrates, including low-molecular weight drugs, affinity ligands, proteins, oligonucleotides, micro-and nanoparticles. Ten contributions from renowned scientists who have embarked on research programs in the exciting area of the application of macromolecules in pharmaceutical chemistry are included in this interdisciplinary Special Issue of Molecules.
Related topics
Related papers
Polymer–drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic
Journal of Controlled Release, 2001
There are now at least seven polymer-drug conjugates that have entered phase I / II clinical trial as anticancer agents. These include N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-doxorubicin (PK1, FCE28068), HPMA copolymer-paclitaxel (PNU 166945), HPMA copolymer-camptothecin, PEG-camptothecin, polyglutamic acid-paclitaxel, an HPMA copolymer-platinate (AP5280) and also an HPMA copolymer-doxorubicin conjugate bearing additionally galactosamine (PK2, FCE28069). The galactosamine is used as a means to target the conjugate to liver for the treatment of primary and secondary liver cancer. Promising early clinical results with lysosomotropic conjugates has stimulated significant interest in this field. Ongoing research is developing (1) conjugates containing drugs that could otherwise not progress due to poor solubility or uncontrollable toxicity; (2) conjugates of agents directed against novel targets; and (3) two-step combinations such as polymer-directed enzyme prodrug therapy (PDEPT) and polymer-enzyme liposome therapy (PELT) that can cause explosive liberation of drug from either polymeric prodrugs or liposomes within the tumour interstitium. Moreover, bioresponsive polymer-based constructs able to promote endosomal escape and thus intracytoplasmic delivery of macromolecular drugs (peptides, proteins and oligonucleotides) are also under study.
Targeting of Tumor Cells and DNA by a Chlorambucil-Spermidine Conjugate1
Cancer Research, 1992
Many tumor cells, including murine ADJ/PC6 plasmacytoma cells, possess an active energy dependent polyamine uptake system which selectively accumulates endogenous polyamines and structurally related compounds. We have attempted to target the cytotoxic drug chloram-l>iiiil to a tumor possessing this uptake system by conjugating it to the polyamine spermidine. Furthermore, since polyamines have a high af finity for DNA, the attachment of spermidine to chlorambucil should also facilitate its targeting to DNA. This was supported by the obser vation that the chlorambucil-spermidine conjugate was approximately 10,000-fold more active than chlorambucil at forming interstrand cross links with naked DNA. In vitro cytotoxicity and in vivo antitumor studies were carried out using the ADJ/PC6 plasmacytoma.
Synthesis, characterization and the release kinetics of antiproliferative agents from polyamidoamine conjugates
Journal of Microencapsulation
Bromopyridazinedione-mediated protein and peptide bioconjugation
Chemical Communications, 2011
Bromopyridazinedione-mediated bioconjugation to a cysteine containing protein and a disulfide containing peptide is described. The conjugates are cleavable in an excess of thiol, including cytoplasmically-relevant concentrations of glutathione, and show a high level of hydrolytic stability. The constructs have the potential for four points of chemical attachment.
The synthesis of polyamide-oligonucleotide conjugate molecules
Nucleic Acids Research, 1990
We have developed methods for the synthesis of peptide-oligodeoxyribonucleotide conjugate molecules in particular, and polyamide-oligonucleotide conjugates in general. Synthesis is carried out by a solid-phase procedure and involves the assembly of a polyamide on the solid support, conversion of the terminal amino group to a protected primary aliphatic hydroxy group by reaction with a,w-hydroxycarboxylic acid derivatives, and finally oligonucleotide synthesis using phosphoramidite chemistry. The conjugate molecules can be used as DNA probes, with the polyamide component carrying one or more non-radioactive markers. These conjugates also have the potential to be used as anti-sense inhibitors of gene expression, with the peptide segment acting as a targeting moiety.
The evolution of polymer conjugation and drug targeting for the delivery of proteins and bioactive molecules
WIREs Nanomedicine and Nanobiotechnology, 2020
Polymer conjugation can be considered one of the leading approaches within the vast field of nanotechnology-based drug delivery systems. In fact, such technology can be exploited for delivering an active molecule, such as a small drug, a protein, or genetic material, or it can be applied to other drug delivery systems as a strategy to improve their in vivo behavior or pharmacokinetic activities such as prolonging the half-life of a drug, conferring stealth properties, providing external stimuli responsiveness, and so on. If on the one hand, polymer conjugation with biotech drug is considered the linchpin of the protein delivery field boasting several products in clinical use, on the other, despite dedicated research, conjugation with low molecular weight drugs has not yet achieved the milestone of the first clinical approval. Some of the primary reasons for this debacle are the difficulties connected to achieving selective targeting to diseased tissue, organs, or cells, which is the main goal not only of polymer conjugation but of all delivery systems of small drugs. In light of the need to achieve better drug targeting, researchers are striving to identify more sophisticated, biocompatible delivery approaches and to open new horizons for drug targeting methodologies leading to successful clinical applications.
Macromolecular prodrug of diflunisal. II. Investigations of in vitro release and of photochemical behaviour
European Journal of Pharmaceutical Sciences, 1996
Polymeric prodrugs: α,β-poly(N-hydroxyethyl)-dl-aspartamide as a macromolecular carrier for some non-steroidal anti-inflammatory agents
International Journal of Pharmaceutics, 1989
The properties as a drug carrier of the biodegradable polymer, a,fl-poly(N-hydroxyethyl)-DL-aspartamide (PHEA) were investigated. Thus, naproxen-and 4-biphenylacetic acid-PHEA adducts were prepared and characterized; drug content was evaluated by both UV and elemental analysis and hydrolysis of the adducts. In vivo analgesic and anti-inflammatory tests indicated that the adducts retain an activity comparable to that of the free drugs, 0378-5173/89/$03.50
Cell kinetic studies of in situ human brain tumors with bromodeoxyuridine
Cytometry, 1985
At the time of surgery, 18 patients with various brain tumors were given a 1-h i.v. infusion of bromodeoxyuridine (BrdUrd), 150-200 mg/m2. At an infusion rate of 200 mg/m2/h, serum BrdUrd levels of 8 microM were achieved. After the infusion, tumor tissue was obtained and divided into two portions. One portion was fixed in 70% ethanol, embedded in paraffin, and sectioned; the sections were deparaffinized, denatured with 2 N HCl, and reacted with monoclonal antibodies against BrdUrd (anti-BrdUrd MAb). BrdUrd-labeled nuclei were demonstrated satisfactorily by an indirect peroxidase method. The other portion was dissociated into single cells with a DNase enzyme cocktail and reacted with FITC-conjugated anti-BrdUrd MAb to determine the percentage of BrdUrd-labeled cells or with chromomycin A3 for DNA analysis. The single-cell suspensions were analyzed by flow cytometry. The fraction of S-phase cells in the tissue sections was similar to both the percentage of BrdUrd-labeled nuclei and th...
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.